source
- Q32 bounces back to claim study success for alopecia drugNearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.BioPharma Dive · 18d ago↗ source
- Health tech funding rises to $7.4B in the first half of 2026Digital health startups raised $7.4 billion in venture funding during the first half of 2026, up $1 billion from the first half of 2025, according to research and venture firm Rock Health. Megaroun…Endpoints · 18d ago↗ source
- Agenus surges on study pivot; Apnimed lines up an IPOAgenus is financially abandoning an ongoing study in late-line colorectal cancer. Elsewhere, an ebola vaccine began human testing and an important Bristol Myers medicine got an FDA decision date.